Your browser doesn't support javascript.
loading
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
Meric-Bernstam, Funda; Lloyd, Michael W; Koc, Soner; Evrard, Yvonne A; McShane, Lisa M; Lewis, Michael T; Evans, Kurt W; Li, Dali; Rubinstein, Lawrence; Welm, Alana; Dean, Dennis A; Srivastava, Anuj; Grover, Jeffrey W; Ha, Min J; Chen, Huiqin; Huang, Xuelin; Varadarajan, Kaushik; Wang, Jing; Roth, Jack A; Welm, Bryan; Govinden, Ramaswamy; Ding, Li; Kaochar, Salma; Mitsiades, Nicholas; Carvajal-Carmona, Luis; Herylyn, Meenhard; Davies, Michael A; Shapiro, Geoffrey I; Fields, Ryan; Trevino, Jose G; Harrell, Joshua C; Doroshow, James H; Chuang, Jeffrey H; Moscow, Jeffrey A.
Afiliação
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Lloyd MW; The Jackson Laboratory, Bar Harbor, Maine.
  • Koc S; Seven Bridges Genomics, Charlestown, Massachusetts.
  • Evrard YA; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • McShane LM; Biometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Lewis MT; Departments of Molecular and Cellular Biology and Radiology, Lester and Sue Smith Breast Center, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
  • Evans KW; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Li D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rubinstein L; Biometric Research Program, DCTD, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Welm A; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Dean DA; Seven Bridges Genomics, Charlestown, Massachusetts.
  • Srivastava A; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Grover JW; Seven Bridges Genomics, Charlestown, Massachusetts.
  • Ha MJ; Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Republic of Korea.
  • Chen H; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Varadarajan K; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Roth JA; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Welm B; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
  • Govinden R; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
  • Ding L; Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.
  • Kaochar S; Department of Medicine, Baylor College of Medicine, Houston, Texas.
  • Mitsiades N; Department of Molecular Cellular Biology, Baylor College of Medicine, Houston, Texas.
  • Carvajal-Carmona L; Department of Biochemistry and Molecular Medicine, University of California, Davis, California.
  • Herylyn M; The Wistar Institute, Philadelphia, Pennsylvania.
  • Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Fields R; Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
  • Trevino JG; Department of Surgery, Virginia Commonwealth University, Richmond, Virginia.
  • Harrell JC; Department of Pathology, Virginia Commonwealth University, Richmond, Virginia.
  • Doroshow JH; Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Chuang JH; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut.
  • Moscow JA; Investigational Drug Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Mol Cancer Ther ; 23(7): 924-938, 2024 Jul 02.
Article em En | MEDLINE | ID: mdl-38641411
ABSTRACT
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Antitumorais Modelo de Xenoenxerto / Neoplasias Limite: Animals / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ensaios Antitumorais Modelo de Xenoenxerto / Neoplasias Limite: Animals / Humans País como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article